Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy

Cancer

Volumn 103, Issue 10, 2005, Pages 2042-2052

  Agarwal, Mayank M ^a   Khandelwal, Niranjan ^a   Mandal, Arup K ^a   Rana, Satyawati V ^a   Gupta, Vivek ^a   Mohan, Vaddi Chandra ^a   Kishore, Gottapu V M K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Androgen antagonists; Body mass index; Computed tomography; Dietary calcium; Orchidectomy; Osteoporosis; Prostate carcinoma

Indexed keywords

ADULT; AGED; ALCOHOLISM; ARTICLE; BODY MASS; BONE DENSITY; CALCIUM INTAKE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LACTOSE INTOLERANCE; MALE; ORCHIECTOMY; OSTEOPOROSIS; PHYSICAL ACTIVITY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; SMOKING;

ADENOCARCINOMA; AGE FACTORS; AGED; ALCOHOL DRINKING; BODY MASS INDEX; BODY WEIGHT; BONE DENSITY; CALCIUM, DIETARY; FOLLOW-UP STUDIES; HUMANS; LACTOSE INTOLERANCE; LUMBAR VERTEBRAE; MALE; MOTOR ACTIVITY; ORCHIECTOMY; OSTEOPOROSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; SMOKING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 18044394578     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21047     Document Type: Article

References (57)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15-36.
2. Reiter RE, deKernion JB. Epidemiology. Etiology and prevention of prostate cancer. In: Walsh PC, Retick AB, Vaughan ED, et al., editors. Campbell's urology, 8th edition. Philadelphia: Saunders, 2002:3003-3024.
3. Ferguson JK, Oesterling JE. Patient evaluation if PSA becomes elevated following radical prostatectomy or radiation therapy. Urol Clin North Am. 1994;21:677-685.
4. Johansson S, Ljunggren E. Prostate carcinoma with hormone treatment. Scand J Urol Nephrol. 1981;15:331-332.
5. Scherr D, Pitts WR, Vaughan ED. Diethylstilbestrol revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol. 2002;167:535-538.
6. Reiner WG, Scot WW, Eggelston JC, et al. Long term survival after hormone therapy for Stage D prostate cancer. J Urol. 1979;122:183-184.
7. Thompson CA, Shanafelt TD, Loprinzi CL. Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist. 2003;8:474-487.
8. Wei JT, Gross M, Jaffe CA, et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology. 1999;54:607-611.
9. Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS. Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer. 2001;91:2238-2245.
10. Daniell HW. Osteoporosis after orchidectomy for prostate cancer. J Urol. 1997;157:439-444.
11. Berutti A, Tucci M, Terrone C, et al. Background to and management of treatment-related bone loss in prostate cancer. Drugs Aging. 2002;19:899-910.
12. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FA. Osteoporosis in men treated with prostate carcinoma receiving androgen deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004;100:892-899.
13. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137-1141.
14. Faulkner KG, Orwell E. Implications in the use of T-scores for the diagnosis of osteoporosis in men. J Clin Densitom. 2002;5:87-93.
15. Krane SM, Holik MF. Metabolic bone disease. In: Fauci AS, Braunwald E, Isselbacher KJ, et al., editors. Harrison's principles of internal medicine. 14th edition. Volume 2. New York: McGraw-Hill, 1998:2247-2253.
16. Rana SV, Bhasin DK, Gupta D, Mehta SK. Assessment of optimal dose of lactose for lactose hydrogen breath test in adult Indians. Indian J Gastroenterol. 1995;14:13-14.
17. Looker AC, Orwell ES, Johnston CC, et al. Prevalence of low femoral bone mineral density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12:1761-1768.
18. Smith MR, McGovern FJ, Zietman AL, et al. Palmidronate to prevent bone loss during androgen deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948-955.
19. Diamond T, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous palmidronate in men with prostate carcinoma receiving combined androgen blockade. A double blind, randomized, placebo controlled cross-over study. Cancer. 2001;92:1444-1450.
20. Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma. Cancer. 1998;83:1561-1566.
21. Frost HM. Dynamics of bone remodeling. In Frost HM, editor. Bone biodynamics. Boston: Little-Brown, 1964:315-334.
22. Rehman O, Lang T, Modin G, Lane NE. Quantitative computed tomography of the lumbar spine and not dual X-ray absorptiometry, is an independent predictor of prevalent vertebral fractures in postmenopausal women with osteopenia receiving long-term glucocorticoid and hormone-replacement therapy. Arthritis Rheum. 2002;46:1292-1297.
23. Clarke NW, McClure J, George NJ. Effects of orchidectomy on skeletal metabolism in metastatic prostate cancer. Scand J Urol Nephrol. 1993;27:475-483.
24. Orwell ES, Oviatt SK, Mann T. The impact of osteophytic and vascular calcification on vertebral mineral density measured in men. J Clin Endocrinol Metab. 1990;70:1202-1207.
25. Daniell HW, Dunn SR, Fergusen DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000;163:181-186.
26. Clarke NW, McClure J, George NJ. Preferential preservation of bone mineralization by LHRH agonists in the treatment of metastatic prostate cancer. Eur Urol 1991;19:114-117.
27. Ahmed SR, Brooman PJC, Shalet SM, et al. Treatment of advanced prostate cancer with LHRH analogue 158630: clinical response and hormone mechanism. Lancet. 1983;2:415-419.
28. Bergman B, Damber JE, Tomic R. Effects of total and subcapsular orchidectomy on serum testosterone and pituitary hormones in patients with prostate cancer. Urol Int 1982;37:139-144.
29. Bracci U, Di Silverio F, Sciarra F, et al. Hormonal pattern in prostate cancer following orchidectomy: 5 year follow up. Br J Urol. 1977;49:161-166.
30. Leukert BP, Raisz LG. Glucorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990;112:352-364.
31. Hedlund P. Side-effects of endocrine treatment and their mechanisms: castration, antiandrogens, and estrogens. Prostate. 2000;45(10 Suppl):32-37.
32. [No authors listed.] NIH consensus conference. Optimal calcium intake. JAMA. 1994;272:1942-1948.
33. Wosje KS, Specker BL. Role of calcium in bone health during childhood. Nutr Rev. 2000;58:253-268.
34. Cummings RC. Calcium intake and bone mass: a quantitative review of evidence. Calcif Tissue Int. 1990;47:194-201.
35. Lau EM, Donnan S, Barker D, Cooper C. Physical activity and calcium intake in fracture of the proximal femur in Hong Kong. BMJ. 1988;297:1441-1443.
36. Wickham CAC, Walsh K, Cooper C, et al. Dietary calcium, physical activity and risk of hip fracture: a prospective study. BMJ. 1989;299:889-892.
37. O'Brien O. Combined calcium and vitamin D supplementation reduces bone loss and fracture incidence in older men and women. Nutr Rev. 1998;56:148-158.
38. Orwell ES, Ovieatt SK, Clung MR, Deftos LJ, Sexton G. The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. Ann Intern Med. 1990;112:29-34.
39. Bauer DC, Browner WS, Cauley JA, et al. Factors associated with appendicular bone mass in older women. Ann Intern Med. 1993;118:657-665.
40. Newcomer A, Hodgson S, McGill D, Thomas P. Lactase deficiency: prevalence in osteoporosis. Ann Intern Med. 1978;89:218-220.
41. Caps MW, Goulding A, Barbezat GO, Campbell AJ. Lactose malabsorption and calcium intake as risk factors for osteoporosis in elderly New Zealand women. NZ Med J. 1991;104:417-419.
42. Honkanen R, Pullkinen P, Jarviene R, et al. Does lactose intolerance predispose to low bone density? A population based study of perimenopausal Finnish women. Bone. 1996;19:23-28.
43. Goulding A, Taylor RW, Keil D, et al. Lactose malabsorption and rate of bone loss in older women. Age Ageing. 1999;28:175-180.
44. Kudlacek S, Freudenthaler O, Weissboeck H, et al. Lactose intolerance: a risk factor for reduced BMD and vertebral fractures? J Gastroenterol. 2002;37:1014-1019.
45. Ross PD. Osteoporosis: frequency, consequences, and risk factors. Arch Intern Med. 1996;156:1399-1411.
46. Glynn NW, Meilahn EN, Charron M, Anderson SJ, Kuller LH, Cauley JA. Determinants of bone mineral density in older men. J Bone Miner Res. 1995;10:1769-1777.
47. Kriska AM, Sandler RB, Cauley JA, et al. The assessment of historical physical activity and its relation with adult bone parameters. Am J Epidemiol. 1988;127:1053-1061.
48. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Exercise and other factors in prevention of hip fracture: the leisure-world study. Epidemiology. 1991;2:16-25.
49. Gregg EW, Cauley JA, Seeley DG, et al. physical activity and osteoporotic fracture risk in older women. Ann Intern Med. 1998;129:81-88.
50. Kujala UM, Kaprio J, Kannus P, Sarna S, Koskenvuo M. Physical activity and osteoporotic hip fracture risk in men. Arch Intern Med. 2000;160:705-708.
51. Seeman E, Melton LJ III, O'Fallon WM. Riggs BL. Risk factors for spinal osteoporosis in men. Am J Med. 1983;75:977-983.
52. Berruti A, Dogliotti L, Terrone C, et al. Changes in BMD, lean body mass and fat content as measured by DEXA in patients with prostate cancer without apparent bone metastasis given androgen deprivation therapy. J Urol. 2002;167:2361-2367.
53. Wade JP. Rheumatology: 15. Osteoporosis. CMAJ. 2001;165:45-50.
54. Oefelein M, Ricchuitti V, Conrad W, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol. 2001;166:1724-1728.
55. Griffin JE, Wilson JD. Disorders of testes. In: Fauci AS, Braunwald E, Isselbacher KJ, et al., editors. Harrison's principles of internal medicine. 14th edition. New York: McGraw-Hill, 1998:2087-2096.
56. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994;79:1693-1700.
57. Akesson K, Ljunghall S, Johnsson B, et al. assessment of biochemical markers of bone metabolism in relation to occurrence of fracture: a retrospective and prospective population based study of women. J Bone Miner Res. 1995;10:1823-1829.